Phreesia, Inc. (NYSE:PHR) General Counsel Sells $88,518.72 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,496 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $25.32, for a total value of $88,518.72. Following the completion of the transaction, the general counsel now directly owns 139,134 shares in the company, valued at $3,522,872.88. This represents a 2.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phreesia Trading Down 0.6 %

PHR opened at $27.45 on Friday. The firm has a market capitalization of $1.61 billion, a PE ratio of -18.68 and a beta of 1.03. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The company’s 50-day moving average is $27.33 and its 200 day moving average is $24.07. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. KeyCorp boosted their price target on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Canaccord Genuity Group raised their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Truist Financial upped their price target on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia has a consensus rating of “Buy” and a consensus price target of $31.33.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently modified their holdings of PHR. Zacks Investment Management purchased a new stake in shares of Phreesia in the third quarter valued at about $631,000. State Street Corp increased its stake in Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after buying an additional 88,517 shares during the last quarter. Wesbanco Bank Inc. increased its position in shares of Phreesia by 76.9% during the fourth quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after acquiring an additional 20,000 shares during the last quarter. Barclays PLC increased its position in shares of Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after acquiring an additional 43,225 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Phreesia by 3.0% during the third quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after acquiring an additional 42,973 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.